文献速递神经技术与安全PETMR

基于多模态PET/MRI影像组学识别帕金森病与多系统萎缩

Identification of Parkinson's disease and multiple system atrophy using multimodal PET/MRI radiomics.
PubMed 文献 · Eur Radiol · 2023-08-03

本研究纳入119例患者(81例帕金森病、38例多系统萎缩),利用脑部[18F]FDG与[11C]CFT PET及T1WI、T2WI、T2-FLAIR MRI提取壳核与尾状核影像组学特征构建模型。五序列联合PET/MRI影像组学模型优于单模态模型;PET/MRI影像组学-临床联合模型在训练集区分帕金森病与多系统萎缩的AUC为0.993,优于临床模型(AUC=0.923,p=0.028),测试集两者无显著差异(AUC=0.860 vs 0.917,p=0.390)。

要点

  • 壳核与尾状核的多模态PET/MRI影像组学可提高帕金森病与多系统萎缩的鉴别诊断效能。
  • 基于影像组学的列线图可用于区分帕金森病与多系统萎缩。
  • PET/MRI影像组学-临床联合模型在识别帕金森病与多系统萎缩中取得良好性能。

核心结论

  • 多模态PET/MRI影像组学在临床上区分帕金森病与多系统萎缩可取得良好性能。

研究设计与样本

  • 研究纳入119例患者(帕金森病81例、多系统萎缩38例),行脑部PET/CT与MRI获取[18F]FDG、[11C]CFT PET代谢图像及T1WI、T2WI、T2-FLAIR结构MRI。

关键影像表现/征象

  • 影像分析包括在MRI上自动分割,并将PET图像与对应MRI共配准。
  • 从壳核与尾状核提取影像组学特征并筛选以构建预测模型。
  • 基于PET/MRI影像组学与临床特征构建列线图。

诊断标准与关键数值

  • 五序列联合PET/MRI影像组学模型优于单模态影像组学模型。
  • PET/MRI影像组学-临床联合模型在训练集区分帕金森病与多系统萎缩的AUC=0.993,优于临床模型(AUC=0.923,p=0.028)。
  • 测试集中PET/MRI影像组学-临床联合模型与临床模型无显著差异(AUC=0.860 vs 0.917,p=0.390)。
  • 训练集中PET/MRI影像组学-临床联合模型与PET/MRI影像组学模型无显著差异(AUC=0.988,p=0.276)。
  • 测试集中PET/MRI影像组学-临床联合模型与PET/MRI影像组学模型无显著差异(AUC=0.860 vs 0.845,p=0.632)。

临床应用与阅片要点

  • 决策曲线分析显示PET/MRI影像组学-临床联合模型具有最高的临床获益。
  • 作者认为多模态PET/MRI影像组学在临床上区分帕金森病与多系统萎缩可取得良好性能。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To construct a machine learning model for differentiating Parkinson's disease (PD) and multiple system atrophy (MSA) by using multimodal PET/MRI radiomics and clinical characteristics.

METHODS: One hundred and nineteen patients (81 with PD and 38 with MSA) underwent brain PET/CT and MRI to obtain metabolic images ([18F]FDG, [11C]CFT PET) and structural MRI (T1WI, T2WI, and T2-FLAIR). Image analysis included automatic segmentation on MRI, co-registration of PET images onto the corresponding MRI. Radiomics features were then extracted from the putamina and caudate nuclei and selected to construct predictive models. Moreover, based on PET/MRI radiomics and clinical characteristics, we developed a nomogram. Receiver operating characteristic (ROC) curves were performed to evaluate the performance of the models. Decision curve analysis (DCA) was employed to access the clinical usefulness of the models.

RESULTS: The combined PET/MRI radiomics model of five sequences outperformed monomodal radiomics models alone. Further, PET/MRI radiomics-clinical combined model could perfectly distinguish PD from MSA (AUC = 0.993), which outperformed the clinical model (AUC = 0.923, p = 0.028) in training set, with no significant difference in test set (AUC = 0.860 vs 0.917, p = 0.390). However, no significant difference was found between PET/MRI radiomics-clinical model and PET/MRI radiomics model in training (AUC = 0.988, p = 0.276) and test sets (AUC = 0.860 vs 0.845, p = 0.632). DCA demonstrated the highest clinical benefit of PET/MRI radiomics-clinical model.

CONCLUSIONS: Our study indicates that multimodal PET/MRI radiomics could achieve promising performance to differentiate between PD and MSA in clinics.

CLINICAL RELEVANCE STATEMENT: This study developed an optimal radiomics signature and construct model to distinguish PD from MSA by multimodal PET/MRI imaging methods in clinics for parkinsonian syndromes, which achieved an excellent performance.

KEY POINTS: •Multimodal PET/MRI radiomics from putamina and caudate nuclei increase the diagnostic efficiency for distinguishing PD from MSA. •The radiomics-based nomogram was developed to differentiate between PD and MSA. •Combining PET/MRI radiomics-clinical model achieved promising performance to identify PD and MSA.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Sun J, Cong C, Li X, et al. Identification of Parkinson's disease and multiple system atrophy using multimodal PET/MRI radiomics. Eur Radiol. 2023. PMID: 37535155. doi:10.1007/s00330-023-10003-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。